RxDoctor Payments Data

Sampath Poreddy

Gastroenterology · Omaha, NENPI 1174726707

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,168 of the $6,215 with a category attached, or 83.2%. 11 manufacturers reported payments, led by Olympus Corporation Of The Americas at 49.6% of the total.

$6,215in general payments, 2019–2025

Across 55 payments — averaging $112.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$3K
  • Boston Scientific$1K
  • Apollo Endosurgery US Inc$731
  • Ovesco Endoscopy USA, Inc.$581
  • Evoke Pharma, Inc.$162
  • Olympus America Inc.$42
  • plus $133 from 5 others

What the payments were for

  • Travel & lodging$5,16883%
  • Food & beverage$1,04617%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,215 in reported general payments places this provider in the 75th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska

Medicare billing

Part B allowed, 2024
$58,914
Medicare patients
153
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$22,461
Omeprazole42$840
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$495
Pantoprazole Sodium25$392
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl18$265
Levofloxacin19$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$41$22,46112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 89 gastroenterology providers in Nebraska.

Other gastroenterology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →